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volume given (iodixanol – 138789 ml vs iogloxate –
1477105 ml; the median values were 110 ml and 120 ml,
respectively). Moreover, the baseline creatinine values are
comparable (iodixanol – 91754 lmol/l vs ioxaglate –
100756 lmol/l; median values: 83 lmol/l vs 92 lmol/l,
respectively). Jo et al. are concerned that the P-values were
not provided for these differences. Our statement that the
differences were not statistically significant may have
escaped their attention; P was greater than 0.05. Moreover,
the iodixanol treated patients were those that received
slightly less contrast media and had slightly lower
baseline creatinine values. Thus, the disadvantageous
effect of giving iodixanol described in our study is not
likely to be explained by the iodixanol-treated patients
receiving greater volumes or having higher baseline
creatinine levels.
Jo et al. feel that the most important restriction of the
discussed study is the difference in risk factors. Due to the
very large patient numbers, even very minor differences
(for instance a difference in age of 64.8710.7 years vs
64.4711.1 years) become highly significant. This under-
scores the power of a large sample size. However, we wish
to point out that all significant differences in risk factors
were compensated for in the calculation of the odds ratio
(Table 4 of the study). The odds ratio calculation indicated
that iodixanol treatment is roughly twice as likely to cause
renal failure (Po0.001).
In particular, Jo et al. are concerned about the higher
incidence of previous renal failure and previous dialysis, which
was more often encountered in the iodixanol treated group.
Although these differences were also compensated for, we
made a separate analysis for only these patients who had
experienced renal failure previously or had required
dialysis before. The outcome was as for the entire group:
renal failure in high-risk patients who previously had renal
failure or needed dialysis was much more likely to occur if
iodixanol was used instead of ioxaglate (Table 4 and Figure 1
of the study).
What we feel is particularly convincing is what
happened to the hospital that switched contrast medium
from ioxaglate to iodixanol (Figure 1 of the study). Renal
failure more than doubled. However, all this evidence does
not preclude the necessity to perform a large randomized
prospective study to solve the question as to which contrast
medium is best for the kidney, we agree.
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Osseous and myeloid metaplasia
in a failed renal allograft
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To the Editor Tousignant et al.1 recently reported a case
of osseous metaplasia in a renal transplant with chro-
nic rejection. A second case of renal allograft osseous
metaplasia is found in the literature.2 We would like to
report a third case, the first to display foci of myeloid
metaplasia, in an end-stage kidney transplant.
A 28-year-old woman with end-stage kidney disease
secondary to diabetic nephropathy underwent living-donor
renal transplantation in 1999. The transplant functioned well
until 2000 when creatinine began to rise and renal function
deteriorated progressively. Repeated biopsies showed epi-
sodes of acute cellular rejection, calcineurin inhibitor toxicity,
and interstitial fibrosis and tubular atrophy. Peritoneal
dialysis was started in 2004. Transplant nephrectomy was
performed 7 years post-transplant for persistent anemia and
failure to thrive.
The transplant showed widespread hemorrhage with
foci of hard material. Light microscopy revealed an
extensively scarred renal parenchyma with patchy necrosis
and negligible residual functional tissue. Arteries showed
Figure 1 | Renal allograft showing osseous metaplasia with
intertrabecular loose adipose tissue containing hematopoietic
lineage cells (H&E stain, original magnification  400).
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chronic transplant arteriopathy with severe intimal fibrosis
and inflammation. Wedge-shaped areas of osseous metaplasia
mostly in the subcapsular region and extending toward the
medulla were found. Mature bone trabeculae were separated
by adipose tissue containing islands of hematopoietic cells
including erythroid and myeloid precursors (Figure 1) and
megakaryocytes.
Osseous metaplasia, in these three cases, was diagnosed at
the time of transplant nephrectomy. It is most likely induced
by chronic ischemic conditions in the setting of vascular and
parenchymal scarring as shown in previous animal models.3
Renal osseous metaplasia can also be associated with
extramedullary hematopoiesis as in the present case.
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